Frequently Asked Questions
The market is segmented based on North America Active Pharmaceutical Ingredients (API) Market, By Molecule (Small Molecule and Large Molecule), Type (Innovative Active Pharmaceutical Ingredients and Generic Innovative Active Pharmaceutical Ingredients), Type of Manufacturer (Captive API Manufacturer and Merchant API Manufacturer), Synthesis (Synthetic Active Pharmaceutical Ingredients and Biotech Active Pharmaceutical Ingredients), Chemical Synthesis (Acetaminophen, Artemisinin, Saxagliptin, Sodium Chloride, Ibuprofen, Losartan Potassium, Enoxaparin Sodium, Rufinamide, Naproxen, Tamoxifen, and Others), Type of Drug (Prescription Drugs and Over-the-Counter), Usage (Clinical and Research), Potency (Low-to-Moderate Potency Active Pharmaceutical Ingredients, and Potent-to-Highly Potent Active Pharmaceutical Ingredient), Therapeutic Application (Cardiology, CNS and Neurology, Oncology, Orthopedic, Endocrinology, Pulmonology, Gastroenterology, Nephrology, Ophthalmology, and Other Therapeutic Application) – Industry Trends and Forecast to 2031.
.
The North America Active Pharmaceutical Ingredient Api Market size was valued at USD 68.32 USD Billion in 2024.
The North America Active Pharmaceutical Ingredient Api Market is projected to grow at a CAGR of 3.6% during the forecast period of 2025 to 2031.
The major players operating in the market include , Dr. Reddy's Laboratories , Sun Pharmaceutical Industries , GlaxoSmithKline plc , Pfizer , Aurobindo Pharma , Sanofi , Lupin , Cipla , BASF SE , Merck KGaA , Novo Nordisk A/S , AbbVie , Alembic Pharmaceuticals Limited , AstraZeneca , Teva Pharmaceutical Industries , Alkem Labs , Saneca Pharmaceuticals , Jubilant Pharmova Limited , Neuland Laboratories Ltd ,.
The market report covers data from the U.S., Canada, and Mexico.
